Ş.İ. Kökcü Karadağ , D. Tekcan , H. Nalçacıoğlu , Ö. Aydoğ , F. Öztürk
{"title":"Eculizumab-Induced Stevens-Johnson Syndrome: The first pediatric case report in the literature","authors":"Ş.İ. Kökcü Karadağ , D. Tekcan , H. Nalçacıoğlu , Ö. Aydoğ , F. Öztürk","doi":"10.1016/j.reval.2025.104602","DOIUrl":null,"url":null,"abstract":"<div><div>Stevens-Johnson Syndrome is a severe mucocutaneous disease that frequently arises in response to medications and is rarely observed. To our knowledge, we report the first pediatric case of SJS induced by Eculizumab, documenting the potential risks associated with this treatment in children and making a significant contribution to the medical literature. A three-year old male patient diagnosed with atypical hemolytic uremic syndrome and treated with Eculizumab exhibited classical symptoms of SJS shortly after receiving his fourth dose. These symptoms included severe oral and labial ulcers, conjunctival hyperemia, and extensive erythematous macular rashes. Initial laboratory tests revealed an abnormal white blood cell count and elevated inflammatory markers, with a subsequent skin biopsy confirming SJS. Immediate initiation of intravenous steroid therapy resulted in substantial improvement in the patient. This report underscores the critical importance of early recognition and management of SJS, particularly in pediatric patients receiving monoclonal antibody therapy. The key lessons highlight the need for healthcare providers to remain vigilant about this rare but potentially fatal adverse effect, and to promptly discontinue treatment and intervene effectively to improve patient outcomes.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"65 6","pages":"Article 104602"},"PeriodicalIF":0.3000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue Francaise d Allergologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877032025003744","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Stevens-Johnson Syndrome is a severe mucocutaneous disease that frequently arises in response to medications and is rarely observed. To our knowledge, we report the first pediatric case of SJS induced by Eculizumab, documenting the potential risks associated with this treatment in children and making a significant contribution to the medical literature. A three-year old male patient diagnosed with atypical hemolytic uremic syndrome and treated with Eculizumab exhibited classical symptoms of SJS shortly after receiving his fourth dose. These symptoms included severe oral and labial ulcers, conjunctival hyperemia, and extensive erythematous macular rashes. Initial laboratory tests revealed an abnormal white blood cell count and elevated inflammatory markers, with a subsequent skin biopsy confirming SJS. Immediate initiation of intravenous steroid therapy resulted in substantial improvement in the patient. This report underscores the critical importance of early recognition and management of SJS, particularly in pediatric patients receiving monoclonal antibody therapy. The key lessons highlight the need for healthcare providers to remain vigilant about this rare but potentially fatal adverse effect, and to promptly discontinue treatment and intervene effectively to improve patient outcomes.
期刊介绍:
La Revue Française d''Allergologie : un véritable forum pour faire connaître des travaux originaux et permettre la diffusion de l''information auprès de toutes les spécialités concernées par les pathologies allergiques. La Revue Française d''Allergologie (8 numéros par an) est au carrefour de nombreuses spécialités - dermatologie, pédiatrie, ORL, pneumologie, ophtalmologie, médecine interne - qui, toutes, ont à traiter des maladies allergiques. Les symptômes des allergies fondés sur des mécanismes communs sont le plus souvent associés et se succèdent chez un même patient. En forte progression depuis 20 ans, les maladies allergiques sont dans l''attente de perfectionnements et d''avancées thérapeutiques qui permettront aux nombreux patients qui en sont atteints de mieux vivre avec leurs allergies. La Revue Française d''Allergologie se veut donc un véritable forum de discussions et d''échanges entre tous les spécialistes confrontés aux pathologies